Description

IGF-1 LR3 – 1 mg

(Insulin-Like Growth Factor-1 Long Arg3 Analog)

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a recombinant analog of human IGF-1, modified to extend its half-life and enhance biological activity in experimental settings. It differs from native IGF-1 by the substitution of arginine for glutamic acid at position 3 and an additional 13-amino-acid extension at the N-terminus, which significantly reduces its binding affinity to IGF-binding proteins (IGFBPs).

These modifications allow IGF-1 LR3 to remain active longer and interact more freely with cellular IGF-1 receptors, promoting sustained anabolic and regenerative signaling in research models investigating growth, repair, and metabolic pathways.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• IGF-1 receptor activation: Binds to IGF-1R, initiating PI3K/Akt and MAPK pathways that regulate cell growth, repair, and survival.

• Reduced IGFBP affinity: Decreased binding to IGFBPs extends duration of activity and enhances receptor availability.

• Anabolic stimulation: Promotes protein synthesis, muscle cell differentiation, and satellite cell activation.

• Cellular regeneration: Supports tissue recovery through proliferation of fibroblasts, myocytes, and neuronal cells.

• Insulin-mimetic action: Influences glucose uptake and nutrient utilization in research models.

---

Potential Benefits (Based on Preclinical Research):

• Enhanced muscle and tissue growth in experimental studies

• Promotion of cellular repair and regeneration

• Improved protein synthesis and nutrient transport

• Support for neuroprotective and metabolic research

• Extended biological activity compared to native IGF-1

• Applications in anabolic, regenerative, and longevity-based investigations

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.